{
    "guideline": {
        "id": "PA166104943",
        "name": "Annotation of DPWG Guideline for risperidone and CYP2D6",
        "source": "DPWG",
        "version": 39,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104943",
        "relatedChemicals": [
            {
                "id": "PA451257",
                "name": "risperidone",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA128",
                "name": "cytochrome P450 family 2 subfamily D member 6",
                "symbol": "CYP2D6"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166302718",
            "name": "Recommendation Annotation PA166302718",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104317,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "3.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302709",
            "name": "Recommendation Annotation PA166302709",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104308,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful."
            ],
            "lookupKey": {
                "CYP2D6": "0.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302722",
            "name": "Recommendation Annotation PA166302722",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104321,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.5"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302713",
            "name": "Recommendation Annotation PA166302713",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104312,
                "html": "<p>The guideline does not provide a recommendation for risperidone in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on risperidone."
            ],
            "lookupKey": {
                "CYP2D6": "1.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302717",
            "name": "Recommendation Annotation PA166302717",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104316,
                "html": "<p>The guideline does not provide a recommendation for risperidone in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on risperidone."
            ],
            "lookupKey": {
                "CYP2D6": "2.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302708",
            "name": "Recommendation Annotation PA166302708",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104307,
                "html": "<p>Use 67% of the normal dose. If problematic side effects originating in the central nervous system occur despite this reduced dose, then reduce the dose further to 50% of the normal dose.</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increased from 16% to 26%. The gene variation increases the plasma concentration of risperidone plus the active metabolite and increases the proportion of risperidone in this ratio, which is more effective at crossing the blood-brain barrier."
            ],
            "lookupKey": {
                "CYP2D6": "0.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302721",
            "name": "Recommendation Annotation PA166302721",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104320,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.25"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302712",
            "name": "Recommendation Annotation PA166302712",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104311,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful."
            ],
            "lookupKey": {
                "CYP2D6": "1.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302725",
            "name": "Recommendation Annotation PA166302725",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104324,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "\u22656.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302716",
            "name": "Recommendation Annotation PA166302716",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104315,
                "html": "<p>The guideline does not provide a recommendation for risperidone in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on risperidone."
            ],
            "lookupKey": {
                "CYP2D6": "2.25"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302720",
            "name": "Recommendation Annotation PA166302720",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104319,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "\u22653.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302711",
            "name": "Recommendation Annotation PA166302711",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104310,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful."
            ],
            "lookupKey": {
                "CYP2D6": "0.75"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302724",
            "name": "Recommendation Annotation PA166302724",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104323,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "\u22655.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "3"
        },
        {
            "id": "PA166302715",
            "name": "Recommendation Annotation PA166302715",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104314,
                "html": "<p>The guideline does not provide a recommendation for risperidone in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on risperidone."
            ],
            "lookupKey": {
                "CYP2D6": "2.0"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302719",
            "name": "Recommendation Annotation PA166302719",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104318,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "4.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302710",
            "name": "Recommendation Annotation PA166302710",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104309,
                "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
            },
            "implications": [
                "There is little evidence to support an increase in side effects caused by the gene variation. The gene variation may lead to a decrease in the required maintenance dose. However, as the effect on the dose is smaller than that of the normal biological variation, action is not useful."
            ],
            "lookupKey": {
                "CYP2D6": "0.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166302723",
            "name": "Recommendation Annotation PA166302723",
            "population": null,
            "classification": {
                "term": "N/A",
                "termId": "guidelineStrength:981501929"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104322,
                "html": "<p>Choose an alternative or titrate the dose according to the maximum dose for the active metabolite (paliperidone) (oral 12 mg/day for adults and children from 15 years of age weighing at least 51 kg and 6 mg/day for children from 15 years of age weighing less than 51 kg; intramuscular 75 mg per 2 weeks).</p>\n"
            },
            "implications": [
                "The percentage of patients with therapy failure increases from 16% to 37%. The gene variation leads to a high ratio of the active metabolite (9-hydroxyrisperidone (paliperidone)) compared to risperidone, which crosses the blood-brain barrier more effectively."
            ],
            "lookupKey": {
                "CYP2D6": "\u22654.0"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166302714",
            "name": "Recommendation Annotation PA166302714",
            "population": null,
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA451257",
                    "name": "risperidone",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452104313,
                "html": "<p>The guideline does not provide a recommendation for risperidone in normal metabolizers.</p>\n"
            },
            "implications": [
                "The guideline does not provide a description of the impact of a normal metabolizer phenotype on risperidone."
            ],
            "lookupKey": {
                "CYP2D6": "1.5"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        }
    ],
    "citations": [
        {
            "pmid": "37002327",
            "title": "Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.",
            "authors": [
                "Beunk Lianne",
                "Nijenhuis Marga",
                "Soree Bianca",
                "de Boer-Veger Nienke J",
                "Buunk Anne-Marie",
                "Guchelaar Henk Jan",
                "Houwink Elisa J F",
                "Risselada Arne",
                "Rongen Gerard A P J M",
                "van Schaik Ron H N",
                "Swen Jesse J",
                "Touw Daan",
                "van Westrhenen Roos",
                "Deneer Vera H M",
                "van der Weide Jan"
            ],
            "journal": "European journal of human genetics : EJHG",
            "year": 2024
        },
        {
            "pmid": "21412232",
            "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
            "authors": [
                "Swen J J",
                "Nijenhuis M",
                "de Boer A",
                "Grandia L",
                "Maitland-van der Zee A H",
                "Mulder H",
                "Rongen G A P J M",
                "van Schaik R H N",
                "Schalekamp T",
                "Touw D J",
                "van der Weide J",
                "Wilffert B",
                "Deneer V H M",
                "Guchelaar H-J"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2011
        }
    ],
    "version": "2024-03-25-16-13"
}